Top

High Blood Pressure & Cardiovascular Prevention

Published in:

01-03-2005 | Review Article

Treating Hypertension with Angiotensin II Receptor Blockers

A Step Ahead of Blood Pressure Reduction?

Authors: Luis M. Ruilope, Dr Massimo Volpe

Published in: High Blood Pressure & Cardiovascular Prevention | Issue 1/2005

Abstract

The clinical use of angiotensin II receptor blockers (ARBs) has resulted in the effective and successful treatment of arterial hypertension, and vast experience has been gained by physicians in this original indication over the last years. Furthermore, promising results have been obtained with the use of ARBs in other clinical conditions, such as type 2 diabetes mellitus with nephropathy, atrial fibrillation, acute myocardial infarction complicated by left ventricular dysfunction and congestive heart failure. On the basis of the available evidence, some representative molecules of this class have been approved for other indications in addition to hypertension in many countries, and many large clinical investigations are underway to confirm the current indications and, even more importantly, to explore whether these compounds may be effectively used in other conditions. The evidence that ARBs can have benefits at any stage of the cardiovascular disease continuum underlies the potential beneficial effects of these agents — independent of blood pressure reduction — in a wide variety of patients at risk of cardiovascular major events.

Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903–13PubMedCrossRef

Isles CG, Walker LM, Beevers GD, et al. Mortality in patients of the Glasgow blood pressure clinic. J Hypertens 1986; 4: 141–56PubMedCrossRef

Blood Pressure Lowering Treatment Trialists’ Collaboration. Effect of angiotensin-converting enzyme inhibitors, calcium antagonists, and other blood pressure lowering drugs: results of prospectively designed overviews of randomized trials. Lancet 2000; 355: 1955–64

Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755–62PubMedCrossRef

PROGRESS Collaborative Group. Randomized trial of perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–41

Yusuf S, Sleight P, Dagenais G, et al. Effects of angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation (HOPE) Study Group. N Engl J Med 2000; 342: 145–53PubMedCrossRef

Fox KM, EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362(9386): 782–8PubMedCrossRef

Andersson OK, Almgren T, Persson B, et al. Survival in treated hypertension: follow up study after two decades. BMJ 1998; 317: 167–71PubMedCrossRef

Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For End-point reduction in hypertension study (LIFE): a randomised trial against atenolol. The LIFE Study Group. Lancet 2002; 359: 995–1003PubMedCrossRef

10.

Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. The SCOPE Study Group. J Hypertens 2003; 21(5): 875–86PubMedCrossRef

11.

Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. The VALUE Trial Group. Lancet 2004; 363(9426): 2022–31PubMedCrossRef

12.

Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall Programme. Lancet 2003; 362: 759–66PubMedCrossRef

13.

Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial investigators. A randomized trial of the Angiotensin II Receptor Blocker Valsartan in Congestive Heart Failure (Val-HeFT). N Engl J Med 2001; 345: 1667–75PubMedCrossRef

14.

Pfeffer MA, McMurray J, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the Valsartan in Acute Myocardial Infarction Trial (VALIANT). N Engl J Med 2003; 349: 1893–906PubMedCrossRef

15.

Dickstein K, Kjekshus J, and the OPTIMAAL Steering Committee. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002; 360: 60–75

16.

Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes: the IDNT Collaborative Study Group. N Engl J Med 2001; 345(12): 851–60PubMedCrossRef

17.

Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study investigators. N Engl J Med 2001; 345(12): 861–9PubMedCrossRef

18.

Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes: the Irbesartan in patients with type 2 Diabetes and Microalbuminuria (IRMA2) Study Group. N Engl J Med 2001; 345: 870–8PubMedCrossRef

19.

Viberti G, Wheeldon NM, for the MicroAlbuminuria Reduction With VALsartan (MARVAL) study investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106: 672–8PubMedCrossRef

20.

Timmermans PB. Pharmacological properties of angiotensin II receptor antagonists. Can J Cardiol 1999; 15Suppl. F: 26F–8FPubMed

21.

Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther 1998; 20: 671–81PubMedCrossRef

22.

Chobanian A, Bakris G, Black H, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289: 2560–71PubMedCrossRef

23.

European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–53

24.

Benz JR, Black HR, Graff A, et al. Valsartan and hydrochlorothiazide in patients with essential hypertension: a multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens 1998; 12(12): 861–6PubMedCrossRef

25.

Conlin PR, Spence JD, Williams B, et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2000; 13(4 Pt 1): 418–26PubMedCrossRef

26.

Ruilope LM, Coca A, Volpe M, et al. ACE inhibition and cardiovascular mortality and morbidity in essential hypertension: the end of the search or a need for further investigations? Am J Hypertens 2002; 15: 367–71PubMedCrossRef

27.

Alderman MH, Madhavan S, Ooi WL, et al. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991; 324(16): 1098–104PubMedCrossRef

28.

Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000; 355: 637–45PubMedCrossRef

29.

Volpe M, Musumeci B, De Paolis P, et al. Angiotensin II AT2 receptor subtype: an uprising frontier in cardiovascular disease? J Hypertens 2003; 21: 1429–43PubMedCrossRef

30.

Kjeldsen SE, Dahlof B, Devereux RB, et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention For Endpoint reduction (LIFE) substudy. JAMA 2002 Sep 25; 288(12): 1491–8PubMedCrossRef

31.

Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction: Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995; 333(25): 1670–6PubMedCrossRef

32.

Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease: the PEACE trial investigators. N Engl J Med 2004; 351(20): 2058–68PubMedCrossRef

33.

Teo K, Yusuf S, Sleight P, et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the ongoing telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment study in ace intolerant subjects with cardiovascular disease (ONTARGET/TRANSCEND) trials. The ONTARGET/TRANSCEND investigators. Am Heart J 2004; 148(1): 52–61PubMedCrossRef

34.

Kizer JR, Dahlof B, Kjeldsen SE, et al. Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. Hypertension 2005; 45: 46–52PubMed

35.

Lindholm LH, Ibsen H, Dahlöf B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. The LIFE Study Group. Lancet 2002; 359: 1004–10PubMedCrossRef

36.

Devereux RB, Dahlof B, Gerdts E, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) trial. Circulation 2004; 110(11): 1456–62PubMedCrossRef

37.

Wachtell K, Olsen MH, Dahlof B, et al. Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. J Hypertension 2002; 20: 405–12CrossRef

38.

Olsen MH, Wachtell K, Bella JN, et al. Albuminuria predicts cardiovascular events independently of left ventricular mass in hypertension: a LIFE substudy. J Hum Hypertens 2004; 18: 453–9PubMedCrossRef

39.

Ibsen H, Wachtell K, Olsen MH, et al. Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. J Hypertens 2004; 22(9): 1805–11PubMedCrossRef

40.

Gerdts E, Oikarinen L, Palmieri V, et al. Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Hypertension 2002; 39(3): 739–43PubMedCrossRef

41.

Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. The SCORE Project Group. Eur Heart J 2003; 24(11): 987–1003PubMedCrossRef

42.

Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet. 2004; 363(9426): 2049–51PubMedCrossRef

43.

Julius S, Kjeldsen SE, Brunner H, et al. VALUE trial: long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. Am J Hypertens 2003; 16(7): 544–8PubMedCrossRef

44.

ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The antihypertensive and lipid-lowering treatment to prevent heart attack trial: major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002; 288: 2981–97

45.

Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611–6PubMedCrossRef

46.

Lindholm LH, Persson M, Alaupovic P, et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003; 21(8): 1563–74PubMedCrossRef

47.

Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004; 43(5): 963–9PubMedCrossRef

48.

Sharma AM, Janke J, Gorzelniak K, et al. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 2002; 40(5): 609–11PubMedCrossRef

49.

Sowers JR. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol 2004; 286(5): H1597–602PubMedCrossRef

50.

Messerli FH, Grossman E, Leonetti G. Antihypertensive therapy and new onset diabetes. J Hypertens 2004; 22(10): 1845–7PubMedCrossRef

51.

Volpe M, Cosentino F, Ruilope LM. Is it time to measure microalbuminuria in hypertension? J Hypertens 2003; 21(7): 1213–20PubMedCrossRef

52.

Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy: the Diabetics Exposed to Telmisartan and Enalapril (DETAIL) Study Group. N Engl J Med 2004; 351(19): 1952–61PubMedCrossRef

53.

Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial. The CHARM Investigators and Committees. Lancet 2003; 362: 772–6PubMedCrossRef

54.

McMurray JJ, Ostergen J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. The CHARM Investigators and Committees. Lancet 2003; 362: 767–71PubMedCrossRef

55.

Yusuf S, Pfeffer MA, Swedberg K, et al. CHARM-preserved effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. The CHARM Investigators and Committees. Lancet 2003; 362(9386): 777–81PubMedCrossRef

Title: Treating Hypertension with Angiotensin II Receptor Blockers
A Step Ahead of Blood Pressure Reduction?
Authors: Luis M. Ruilope
Dr Massimo Volpe
Publication date: 01-03-2005
Publisher: Springer International Publishing
Published in: High Blood Pressure & Cardiovascular Prevention / Issue 1/2005
Print ISSN: 1120-9879
Electronic ISSN: 1179-1985
DOI: https://doi.org/10.2165/00151642-200512010-00003

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Treating Hypertension with Angiotensin II Receptor Blockers

A Step Ahead of Blood Pressure Reduction?

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2005

Angiotensin II Signalling in Bartter’s and Gitelman’s Syndromes

The Limitations of Transferring Evidence from Clinical Trials to the Care of Individual Patients

Opinion and Evidence in Hypertension and Cardiovascular Disease Prevention

Tolerability of Nebivolol in Head-To-Head Clinical Trials Versus Other Cardioselective β-Blockers in the Treatment of Hypertension

Industry Pulse

Head-to-Head Intervention Trials in Hypertension